Table 2.

Current Recommendations Regarding the Duration of Anticoagulation Therapy for DVT and PE

Three Months of anticoagulation recommendedIndefinite Anticoagulation Recommended
Patients treated for isolated calf-vein thrombosis
Patients with a provoked proximal DVT or PE (transient risk factor was present)
Patients with an unprovoked VTE who are at high risk for bleeding
Caucasian women with an unprovoked VTE who have 1 or fewer points using the HERDOO2 decision rule #5
Patients with first-time proximal DVT or PE in the setting of a persisting risk factor (eg, active cancer)
Men who have a first-time unprovoked proximal DVT or PE
Caucasian women with first-time unprovoked VTE and 2 or more points using the HERDOO2 decision rule #5
Patients who meet the criteria for having antiphospholipid antibody syndrome
Patients being evaluated for CTEPH because of ongoing dyspnea.
Until further research has been completed, the use of the HERDOO2 decision rule to risk-stratify women with unprovoked VTE should be applied only to Caucasian women.
  • CTEPH, chronic thromboembolic pulmonary hypertension; DVT, deep vein thrombosis; PE, pulmonary embolism; VTE, venous thromboembolism.

  • *Information adapted from the following sources: Rodger MA, Kahn SR, Wells PS, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. Can Med Assoc J. 2008;179(5):417-426; Konstantinides S, Meyer G, Becattini C, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2019. doi:10.1093/eurheartj/ehz405.